Abstract 570P
Background
Osimertinib is the standard of care for the first-line treatment of advanced NSCLC (aNSCLC) patients (pts) with epidermal growth factor receptor (EGFR) activating mutations. Limited Chinese patients’ data in real-world setting are available regarding the effectiveness of osimertinib in EGFRm aNSCLC, especially in patients harboring uncommon EGFR mutations.
Methods
Patients treated with first-line osimertinib were retrospectively collected from 11 hospitals in China between March 25, 2017 and December 31, 2022. Mutations were categorized as EGFR activating mutations (19del/21L858R; cohort 1) and uncommon mutations (G719X, L861Q, S768I, 20ins, de novo T790M; cohort 2). Patient characteristics, progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), and disease control rate (DCR) were analyzed.
Results
A total of 385 patients with stage IV NSCLC were included, 308 pts in cohort 1 and 77 pts in cohort 2. The median age was 59 years, 214 (55.6%) were female, 350 (90.9%) were adenocarcinoma, and 141 (36.6%) patients had documented brain metastases (35 patients received whole-brain radiotherapy). In cohort 1, the median follow-up was 32.8 months and mPFS was 20.8 months (19del subgroup: 22.7 months; 21L858R subgroup: 14.8 months). For patients with/without documented brain metastases, mPFS was 15.6 months and 23.4 months, respectively. mTTP was 21.5 months for all patients. ORR was 75.6%, including 3 patients with CR and 230 patients with PR. DCR was 94.2%. In cohort 2, ORR was 64.9% (50 patients with SD) and DCR was 93.5%. with a median follow-up of 8.3 months, both mPFS and mTTP were 7.3 months. No new safety signals were observed. Table: 570P
Cohort 1 (19del, 21L858R) | Cohort 2 (G719X, L861Q, S768I, 20ins, de novo T790M) | |
n (%) | 308 (80%) | 77 (20%) |
CRPRSDPD | 3 (0.9%)230 (74.7%)57 (18.5%)18 (5.9%) | 0 (0%)50 (64.9%)22 (28.6%)5 (6.5%) |
ORR (%) | 75.6% | 64.9% |
DCR (%) | 94.2% | 93.5% |
mPFS (month) | 20.8m | 7.3m |
mTTP(month) | 21.5m | 7.3m |
Conclusions
The result is consistent with FLAURA study for patients with EGFR-activating mutation. Osimeritinib showed clinical activity in patients with EGFR uncommon mutations as first-line treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract